Angle
ANGLE unveils new strategy with executive reshuffle and name change to CelLBx Health
October 13, 2025Business Services Angle
ANGLE has outlined a revised business strategy centred on tighter cost management, accelerated commercial execution, and long-term sustainability. The update …
ANGLE’s Parsortix system used in new cancer biology research
June 10, 2025Medical Communications, Research and Development Angle, Oncology, Parsortix system, R&D, biotech, oncology, scientific journals
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour cell (CTC) harvesting system in …
INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA
August 1, 2024Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma
Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
ANGLE signs commercial agreement with AstraZeneca
April 26, 2024Business Services Angle, AstraZeneca, Pharmacy, commercial agreement
ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology …
Abbott teams up with Angle for metastatic breast cancer study
February 6, 2018Manufacturing and Production, Research and Development Abbott, Angle, Cancer, breast cancer, pharma
Abbott is set to join forces with liquid biopsy medtech firm Angle to collaborate on a study into metastatic breast …
